Research Study: Clinical Evaluation of mTORC1 Inhibition for Geroprotection Everolimus Aging Study (EVERLAST), Principal Investigator: Adam R. Konopka, Ph. D.
As people age, their risk for developing chronic diseases and conditions increases. The goal of this study is to determine if taking the drug everolimus can help improve or maintain health as we age. We are recruiting insulin resistant or pre-diabetic adults to participate in the EVERLAST study.
You may qualify to participate if you meet the following criteria:
- Are between the ages of 55-80 years old
- Insulin Resistant: HOMA-IR ≥ 1.5
- Higher than normal blood sugar (100-125 mg/dL) or HbA1c (5.7-6.4%) but are otherwise healthy
- Are not taking medications to lower glucose or that prolong bleeding
Volunteers will complete a medical screening visit (for free). Those with known heart/liver/kidney disease, diabetes, bleeding disorders, cancer or other major illnesses do not qualify for the study.
Once enrolled in the study, participants will:
- Take the drug everolimus or placebo once daily and once weekly for 24 weeks
- Be monitored regularly before, during, and after the study
- Receive several health and research tests, including exercise testing, blood and muscle sampling, heart and brain imaging, glucose testing and a body composition scan
- Receive compensation up to $2000 for your time
All study activities have received authorization by the FDA and IRB as required for research with investigational drugs.
Unsure if you fit these criteria? Interested in participating or learning more? Contact the study team at everlast@medicine.wisc.edu! We can help identify if you may be eligible and answer any questions.
Funding for the research is provided by National Institute on Aging (U01AG076941) to principal investigator Adam R. Konopka, PhD in the Department of Medicine, Division of Geriatrics.
